IL160970A0 - Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination - Google Patents

Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Info

Publication number
IL160970A0
IL160970A0 IL16097002A IL16097002A IL160970A0 IL 160970 A0 IL160970 A0 IL 160970A0 IL 16097002 A IL16097002 A IL 16097002A IL 16097002 A IL16097002 A IL 16097002A IL 160970 A0 IL160970 A0 IL 160970A0
Authority
IL
Israel
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
IL16097002A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL160970A0 publication Critical patent/IL160970A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL16097002A 2001-11-06 2002-11-05 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination IL160970A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17
PCT/EP2002/012343 WO2003039599A1 (en) 2001-11-06 2002-11-05 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Publications (1)

Publication Number Publication Date
IL160970A0 true IL160970A0 (en) 2004-08-31

Family

ID=26988512

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16097002A IL160970A0 (en) 2001-11-06 2002-11-05 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
IL160970A IL160970A (en) 2001-11-06 2004-03-18 Combinations comprising cyclooxygenase-2 inhibitor and histone deacetylase inhibitor, use thereof in the preparation of medicaments and pharmaceutical compositions comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160970A IL160970A (en) 2001-11-06 2004-03-18 Combinations comprising cyclooxygenase-2 inhibitor and histone deacetylase inhibitor, use thereof in the preparation of medicaments and pharmaceutical compositions comprising them

Country Status (22)

Country Link
US (3) US7402603B2 (de)
EP (1) EP1443967B1 (de)
JP (1) JP4413614B2 (de)
KR (1) KR100937064B1 (de)
CN (1) CN100457183C (de)
AT (1) ATE352319T1 (de)
AU (1) AU2002351844B2 (de)
BR (1) BR0213932A (de)
CA (1) CA2461373A1 (de)
CY (1) CY1106508T1 (de)
DE (1) DE60217895T2 (de)
DK (1) DK1443967T3 (de)
ES (1) ES2280597T3 (de)
HU (1) HUP0402370A3 (de)
IL (2) IL160970A0 (de)
MX (1) MXPA04004312A (de)
NO (1) NO20042148L (de)
NZ (1) NZ544689A (de)
PL (1) PL205853B1 (de)
PT (1) PT1443967E (de)
RU (1) RU2311200C2 (de)
WO (1) WO2003039599A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
JP2006528952A (ja) * 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
NZ552501A (en) * 2004-08-11 2010-03-26 Kyorin Seiyaku Kk Novel cyclic aminobenzoic acid derivative
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
BRPI0613429A2 (pt) * 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
JP5431926B2 (ja) 2006-06-12 2014-03-05 ノバルティス アーゲー Ｎ−ヒドロキシ−３−［４−［［［２−（２−メチル−１ｈ−インドール−３−イル）エチル］アミノ］メチル］フェニル］−２ｅ−２−プロペンアミドの製造方法およびその出発物質
US7989494B2 (en) * 2006-06-12 2011-08-02 Novartis Ag Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
TR200809829T1 (tr) * 2006-06-28 2009-06-22 Novartis Ag HDAC inhibitörlerinin lenfoma tedavisine yönelik olarak kullanımı
JPWO2008023438A1 (ja) 2006-08-25 2010-01-07 旭硝子株式会社 １，２−ジアルコキシ−３−フルオロベンゼンの製造方法
MX2009008347A (es) 2007-02-06 2009-10-19 Lixte Biotechnology Holdings I Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
PE20090519A1 (es) * 2007-02-15 2009-05-29 Novartis Ag Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
US8143445B2 (en) 2007-10-01 2012-03-27 Lixte Biotechnology, Inc. HDAC inhibitors
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2013157528A1 (ja) * 2012-04-16 2013-10-24 トーアエイヨー株式会社 ２環性化合物
US10532050B2 (en) 2013-04-09 2020-01-14 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
JP2018531213A (ja) 2015-03-13 2018-10-25 フォーマ セラピューティクス，インコーポレイテッド Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
JP2005510517A (ja) 2005-04-21
ATE352319T1 (de) 2007-02-15
IL160970A (en) 2010-06-30
EP1443967A1 (de) 2004-08-11
CA2461373A1 (en) 2003-05-15
RU2004117170A (ru) 2005-04-20
US20080227845A1 (en) 2008-09-18
AU2002351844B2 (en) 2006-12-21
NO20042148L (no) 2004-08-04
CN1578674A (zh) 2005-02-09
CY1106508T1 (el) 2012-01-25
RU2311200C2 (ru) 2007-11-27
NZ544689A (en) 2007-08-31
DE60217895T2 (de) 2007-07-05
MXPA04004312A (es) 2005-05-16
US20050032899A1 (en) 2005-02-10
DE60217895D1 (en) 2007-03-15
ES2280597T3 (es) 2007-09-16
PT1443967E (pt) 2007-04-30
US7402603B2 (en) 2008-07-22
HUP0402370A3 (en) 2008-04-28
PL205853B1 (pl) 2010-06-30
HUP0402370A2 (hu) 2005-02-28
US20090192211A1 (en) 2009-07-30
JP4413614B2 (ja) 2010-02-10
DK1443967T3 (da) 2007-04-16
EP1443967B1 (de) 2007-01-24
KR100937064B1 (ko) 2010-01-15
CN100457183C (zh) 2009-02-04
KR20050043744A (ko) 2005-05-11
BR0213932A (pt) 2004-08-31
PL368539A1 (en) 2005-04-04
WO2003039599A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
DE60217895D1 (en) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
JO2434B1 (en) New retinoids to treat emphysema
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
BR9914044A (pt) ésteres tetrahidropirido
WO2008114262A3 (en) Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
EP1461313A4 (de) Inhibitoren von humanem adam-10
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
HK1087010A1 (en) Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
HUP0102322A2 (hu) Fehérje farnezil-transzferáz és HMG-CoA reduktáz inhibitorok kombinációi és alkalmazásuk rák kezelésére
MX2007000120A (es) Composicion herbacea.
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona
WO2003077841A3 (en) Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
MD2323F1 (en) Use of S-ethyl isothiouronium bromide (isoturon) as uterotonic preparation for treatment of uterine hemorrhages in case of uterine myoma
EP1232748A4 (de) Subsituierte nitrobenzol derivate mit medikamentöser oder anderer wirkung